Drug Patents owned by Acadia Pharms Inc

1. List of Nuplazid drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7923564 ACADIA PHARMS INC Synthesis of N-(4-fluorobenzyl)-N-(1-methylpiperidin-4-yl)-N′-(4-(2-methylpropyloxy) phenylmethyl)carbamide and its tartrate salt and crystalline forms
Sep, 2025

(2 years from now)

US7732615 ACADIA PHARMS INC N-(4-fluorobenzyl)-N-(1-methylpiperidin-4-yl)-N′-(4-(2-methylpropyloxy)phenylmethyl)carbamide and its tartrate salt and crystalline forms
Jun, 2028

(5 years from now)

US7601740 ACADIA PHARMS INC Selective serotonin 2A/2C receptor inverse agonists as therapeutics for neurodegenerative diseases
Apr, 2030

(7 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9765053 ACADIA PHARMS INC Methods of treatment using selective 5-HT2A inverse agonists
Jul, 2022

(7 months ago)

US8921393 ACADIA PHARMS INC Selective serotonin 2A/2C receptor inverse agonists as therapeutics for neurodegenerative diseases
Jan, 2024

(9 months from now)

US8618130 ACADIA PHARMS INC Selective serotonin 2A/2C receptor inverse agonists as therapeutics for neurodegenerative diseases
Jan, 2024

(9 months from now)

US9566271 ACADIA PHARMS INC Selective serotonin 2A/2C receptor inverse agonists as therapeutics for neurodegenerative diseases
Jan, 2024

(9 months from now)

US10028944 ACADIA PHARMS INC Selective serotonin 2A/2C receptor inverse agonists as therapeutics for neurodegenerative diseases
Jan, 2024

(9 months from now)

US7659285 ACADIA PHARMS INC Selective serotonin 2A/2C receptor inverse agonists as therapeutics for neurodegenerative diseases
Aug, 2026

(3 years from now)

US10953000 ACADIA PHARMS INC Combination of pimavanserin and cytochrome P450 modulators
Mar, 2037

(14 years from now)

US10517860 ACADIA PHARMS INC Combination of pimavanserin and cytochrome P450 modulators
Mar, 2037

(14 years from now)

US10646480 ACADIA PHARMS INC Formulations of pimavanserin
Aug, 2038

(15 years from now)

US10849891 ACADIA PHARMS INC Formulations of pimavanserin
Aug, 2038

(15 years from now)

US10449185 ACADIA PHARMS INC Formulations of pimavanserin
Aug, 2038

(15 years from now)

US11452721 ACADIA PHARMS INC Formulations of pimavanserin
Aug, 2038

(15 years from now)

Drugs and Companies using PIMAVANSERIN TARTRATE ingredient

Market Authorisation Date: 29 April, 2016

Treatment: Treatment of hallucinations and delusions associated with parkinson's disease psychosis; Treatment of a neurodegenerative disease or a symptom thereof; Treatment of psychosis or a symptom thereof; Treatment of parkinson's disease psychosis

Dosage: TABLET;ORAL

How can I launch a generic of NUPLAZID before it's patent expiration?
More Information on Dosage

NUPLAZID family patents

62

United States

10

China

10

European Union

7

Russia

7

Japan

6

Canada

6

Australia

5

Spain

5

Korea, Republic of

5

South Africa

5

Denmark

4

Mexico

4

Hong Kong

3

Singapore

3

Brazil

3

New Zealand

3

Austria

3

Slovenia

2

Portugal

2

Germany

2

Sweden

2

Cyprus

2

Poland

1

Israel

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in